Iopamidol
Iopamidol, Isovue (iopamidol) is a small molecule pharmaceutical. Iopamidol was first approved as Isovue-m 200 on 1985-12-31.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Iopamidol, Isovue (discontinued: Iopamidol, Isovue)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Iopamidol
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ISOVUE-M 200 | Bracco Diagnostics | N-018735 RX | 1985-12-31 | 1 products, RLD, RS |
| ISOVUE-300 | Bracco Diagnostics | N-018735 RX | 1985-12-31 | 1 products, RLD, RS |
| ISOVUE-370 | Bracco Diagnostics | N-018735 RX | 1985-12-31 | 1 products, RLD, RS |
| ISOVUE-M 300 | Bracco Diagnostics | N-018735 RX | 1985-12-31 | 1 products, RLD, RS |
| ISOVUE-200 | Bracco Diagnostics | N-018735 RX | 1987-07-07 | 1 products, RLD, RS |
| ISOVUE-250 | Bracco Diagnostics | N-018735 RX | 1992-07-06 | 1 products, RLD, RS |
| ISOVUE-300 | Bracco Diagnostics | N-020327 RX | 1994-10-12 | 1 products, RLD, RS |
| ISOVUE-370 | Bracco Diagnostics | N-020327 RX | 1994-10-12 | 1 products, RLD, RS |
Show 3 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| iopamidol | ANDA | 2024-04-18 |
| isovue | New Drug Application | 2024-12-19 |
| isovue-m | New Drug Application | 2022-11-03 |
| isovue-m 200 | New Drug Application | 2017-01-17 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
51 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | 1 | 2 | 2 | 5 |
| Coronary artery disease | D003324 | — | I25.1 | — | 1 | — | 1 | 3 | 5 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | 1 | 1 | 3 | — | 5 |
| Chronic renal insufficiency | D051436 | — | N18 | — | 1 | — | 2 | 1 | 4 |
| Coronary stenosis | D023921 | EFO_1000882 | — | — | — | — | 3 | — | 3 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | 1 | — | 2 | — | 3 |
| Chronic pain | D059350 | HP_0012532 | — | — | — | — | 1 | 1 | 2 |
| Body weight | D001835 | EFO_0004338 | — | — | — | — | 2 | — | 2 |
| Acute kidney injury | D058186 | HP_0001919 | N17 | — | — | 1 | 1 | — | 2 |
| Healthy volunteers/patients | — | — | — | 1 | 1 | — | 1 | — | 2 |
Show 10 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | 1 | 1 | — | 1 | 3 |
| Carcinoma | D002277 | — | C80.0 | 1 | — | 1 | — | 1 | 3 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | — | — | 1 | — | 1 | 2 |
| Computed tomography angiography | D000072226 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 1 | 2 | — | — | — | 3 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 1 | — | — | 1 | 2 |
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | — | 1 | — | — | — | 1 |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | 1 | — | — | — | 1 |
| Heart failure | D006333 | HP_0001635 | I50 | — | 1 | — | — | — | 1 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | 1 | — | — | — | 1 |
| Duodenal neoplasms | D004379 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | — | — | — | 1 | 3 |
| Triple negative breast neoplasms | D064726 | — | — | 1 | — | — | — | — | 1 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 1 | — | — | — | — | 1 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | 1 | — | — | — | — | 1 |
| Urologic neoplasms | D014571 | — | C64-C68 | 1 | — | — | — | — | 1 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | — | — | — | — | 1 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | — | — | 3 | 3 |
| Coronary disease | D003327 | — | — | — | — | — | — | 2 | 2 |
| Ischemia | D007511 | EFO_0000556 | — | — | — | — | — | 1 | 1 |
| Intraoperative complications | D007431 | — | — | — | — | — | — | 1 | 1 |
| Postoperative complications | D011183 | — | — | — | — | — | — | 1 | 1 |
| Gallstones | D042882 | EFO_0004210 | — | — | — | — | — | 1 | 1 |
| Laparoscopic cholecystectomy | D017081 | — | — | — | — | — | — | 1 | 1 |
| Cholelithiasis | D002769 | EFO_0004799 | K80 | — | — | — | — | 1 | 1 |
| Cholecystolithiasis | D041761 | EFO_1000864 | — | — | — | — | — | 1 | 1 |
| Biliary tract diseases | D001660 | EFO_0009534 | K83.9 | — | — | — | — | 1 | 1 |
Show 7 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Iopamidol |
| INN | iopamidol |
| Description | Iopamidol is a benzenedicarboxamide compound having N-substituted carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and a (2S)-2-hydroxypropanamido group at the 5-position. It has a role as a radioopaque medium, an environmental contaminant and a xenobiotic. It is a benzenedicarboxamide, an organoiodine compound and a pentol. |
| Classification | Small molecule |
| Drug class | iodine-containing contrast media |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@H](O)C(=O)Nc1c(I)c(C(=O)NC(CO)CO)c(I)c(C(=O)NC(CO)CO)c1I |
Identifiers
| PDB | — |
| CAS-ID | 60166-93-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1200932 |
| ChEBI ID | 31711 |
| PubChem CID | 65492 |
| DrugBank | DB08947 |
| UNII ID | JR13W81H44 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,012 documents
View more details
Safety
Black-box Warning
Black-box warning for: Isovue
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,992 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use